Zevra Therapeutics, Inc. (ZVRA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 48.63M USD | Liabilities, Current |
| Cash and equivalents | 145.32M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 76.25M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 2.45M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $48.63M | $145.32M | $76.25M | (m) | $2.45M | (m) |
| 2026-03-31 | (m) | $47.03M | $95.59M | $105.02M | (m) | $2.31M | (m) |
| 2025-12-31 | (m) | $39.28M | $62.41M | $128.60M | (m) | $1.74M | (m) |
| 2025-09-30 | (m) | $26.11M | $54.44M | $145.07M | (m) | $1.37M | (m) |
| 2025-06-30 | (m) | $28.83M | $47.71M | $154.90M | (m) | $1.11M | (m) |
| 2025-03-31 | (m) | $26.98M | $37.34M | $25.29M | (m) | $2.56M | (m) |
| 2024-12-31 | $79.67M | $34.06M | $33.78M | $35.71M | $10.18M | $1.97M | 2.34× |
| 2024-09-30 | (m) | $34.48M | $54.04M | $35.34M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $30.45M | $39.26M | $10.00M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $29.91M | $42.85M | $9.87M | (m) | (m) | (m) |
| 2023-12-31 | $83.86M | $73.72M | $43.05M | $24.69M | $16.12M | $9.84M | 1.14× |
| 2023-09-30 | $86.04M | $21.71M | $43.27M | $39.67M | $3.10M | (m) | 3.96× |
| 2023-06-30 | $88.19M | $18.25M | $66.20M | $20.70M | $1.30M | (m) | 4.83× |
| 2023-03-31 | (m) | $15.62M | $40.18M | $34.40M | (m) | (m) | (m) |
| 2022-12-31 | $89.55M | $11.73M | $65.47M | $16.90M | $7.18M | (m) | 7.64× |
| 2022-09-30 | (m) | $8.43M | $70.06M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $7.16M | $76.78M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $2.94M | $100.24M | $1.34M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $4.23M | $112.35M | (m) | $1.42M | (m) | (m) |
| 2021-09-30 | (m) | $3.70M | $131.50M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $5.96M | $132.29M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $4.24M | $75.92M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $7.54M | $4.21M | (m) | $2.44M | (m) | (m) |
| 2020-09-30 | (m) | $70.80M | $5.27M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $72.55M | $6.37M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $75.56M | $2.36M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $5.43M | $3.22M | (m) | $1.68M | (m) | (m) |
| 2019-09-30 | (m) | $10.41M | $6.52M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $14.97M | $7.31M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $15.17M | $13.44M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $12.00M | $18.41M | $3.26M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $18.32M | $1.79M | $11.24M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $17.60M | $16.50M | $11.70M | (m) | (m) | (m) |
| 2018-03-31 | $36.13M | $13.81M | $8.75M | $25.87M | $1.51M | (m) | 2.62× |
| 2017-12-31 | $44.23M | $11.51M | $10.87M | $31.36M | $2.00M | (m) | 3.84× |
| 2017-09-30 | $47.74M | $6.65M | $7.83M | $37.41M | $2.50M | (m) | 7.18× |
| 2017-06-30 | (m) | $6.59M | $12.39M | $41.11M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $4.81M | $12.88M | $48.24M | (m) | (m) | (m) |
| 2016-12-31 | $72.77M | $6.64M | $16.76M | $51.00M | $5.00M | (m) | 10.96× |
| 2016-09-30 | (m) | $5.70M | $20.85M | $42.68M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $7.39M | $27.51M | $55.13M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $5.84M | $77.33M | $33.67M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $8.34M | $32.32M | $19.00M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $6.79M | $59.01M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $4.91M | $64.22M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $4.03M | $10.27M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $3.94M | $10.26M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $19.02M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $22.95M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $1.05M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $1.97M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $2.54M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |